Adjusted Indirect Comparison Between Epcoritamab‐R 2 and Tafasitamab‐R 2 in Relapse/Refractory Follicular Lymphoma
Hematological Oncology · 2026
DOI: 10.1002/hon.70282 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Hematological Oncology, 2026. Verfasst von Leonidas Benetatos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ηematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Treatment of relapsed refractory follicular lymphoma (R/R FL) still remains challenging. Several strategies have been used against R/R FL. Recently, two chemotherapy‐free regimens have gained space, epcoritamab‐lenalidomide‐rituximab (Epco‐R 2 ) and tafasitamab‐lenalidomide‐rituximab (Tafa‐R 2 ). Herein, we performed an indirect trial comparison (ITC) between the two regimens using the Bucher method as they both have the common comparator arm R 2 . The ITC between the two study arms showed an overall response rate (ORR; p = 0.020), and complete remission rates (CR; p < 0.0001), in favor of Epco‐R 2 . Analysis regarding time to next treatment (TTNT) interval also favored Epco‐R 2 ( p = 0.0011). The ITC in the progression free survival (PFS) context showed the anchored comparison favored Epco‐R 2 over Tafa‐R 2 [HR 0.51 (95% CI 0.31–0.86)], p = 0.011, a finding more pronounced in patients with progression of disease within 24 months (POD24) negativity. Regarding the safety profile, Epco‐R 2 was associated with more hematological toxicity and infections, whereas, Tafa‐R 2 was associated with more COVID‐19 infections probably reflecting the pandemic era enrollment timing. In conclusion, Epco‐R 2 is more effective in terms of treatment outcomes, but comes with greater toxicity. Tafa‐R 2 seems more suitable for patients with limited bone marrow reserves, patients who wish to avoid hospitalization, patients at a higher risk for cytokine release syndrome, and patients with high‐risk infection vulnerability. Finally, this is not a direct comparison of two therapeutic regimens and the results should be cautiously interpreted. Treatment choice should be decided on a case‐by‐case scenario based on several different variables.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ηematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
- Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.
- Hematology Laboratory, Unit of Molecular Biology and Translational Flow Cytometry, University Hospital of Ioannina, Ioannina, Greece.
ORCID-Profile: Leonidas Benetatos, Vasileios Georgoulis, Eleftheria Hatzimichael
Zitieren
APA
Benetatos, L., Apostolidou, E., Georgoulis, V., Markopoulos, G. S., Dimitriadis, S., Hatzimichael, E., & Kapsali, E. (2026). Adjusted Indirect Comparison Between Epcoritamab‐R 2 and Tafasitamab‐R 2 in Relapse/Refractory Follicular Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70282
Vancouver
Benetatos L, Apostolidou E, Georgoulis V, Markopoulos GS, Dimitriadis S, Hatzimichael E, et al. Adjusted Indirect Comparison Between Epcoritamab‐R 2 and Tafasitamab‐R 2 in Relapse/Refractory Follicular Lymphoma. Hematological Oncology. 2026. doi:10.1002/hon.70282
BibTeX
@article{Benetatos2026,
author = {Benetatos, Leonidas and Apostolidou, Elisavet and Georgoulis, Vasileios and Markopoulos, Georgios S and Dimitriadis, Savvas and Hatzimichael, Eleftheria and Kapsali, Eleni},
title = {Adjusted Indirect Comparison Between Epcoritamab‐R 2 and Tafasitamab‐R 2 in Relapse/Refractory Follicular Lymphoma},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70282}
}
EUVIMED